文献速递消化内镜消化道肿瘤与早癌

系统评价与荟萃分析评估经口出口缩小术是否符合ASGE PIVI阈值

Association for Bariatric Endoscopy systematic review and meta-analysis assessing the American Society for Gastrointestinal Endoscopy preservation and incorporation of valuable endoscopic innovations thresholds for transoral outlet reduction.
PubMed 文献 · Gastrointest Endosc · 2025-07-25

本研究由减重内镜协会与ASGE技术委员会合作,通过系统评价和荟萃分析评估经口出口缩小术(TORe)是否满足ASGE PIVI文件对内镜减重疗法的性能阈值。结果显示,TORe后12个月汇总总体重减轻(TWL)为8.9%,达到5%的PIVI阈值;汇总严重不良事件率为1.5%,满足≤5%的阈值,支持其临床 adoption。

要点

  • TORe后12个月TWL为8.9%(95%CI 6.5%-11.3%),达到PIVI的5%阈值。
  • 严重不良事件率为1.5%(95%CI 0.8%-2.6%),满足PIVI的≤5%阈值。
  • 荷包缝合模式TWL为12.8%,显著优于非荷包缝合的6.5%。

核心结论

  • TORe在有效性和安全性上均满足ASGE PIVI阈值,支持其临床采用,且不限于特定设备。
  • 对于缝合式TORe,荷包缝合模式可能带来更优的减重效果。

研究设计与样本

  • 系统评价与荟萃分析,由减重内镜协会与ASGE技术委员会合作完成。
  • 有效性分析纳入12项研究共1154例患者;安全性分析纳入15项研究共1373例患者。

主要发现

  • TORe后12个月汇总TWL为8.9%(95%CI 6.5%-11.3%;P < .0001)。
  • 按设备亚组:缝合式TORe(11项研究,1043例)TWL为8.9%(95%CI 6.2%-11.5%);折叠式TORe(1项研究,110例)TWL为9.5%(95%CI 7.8%-11.3%);P = .07。
  • 按缝合模式亚组:荷包缝合(5项研究,687例)TWL为12.8%(95%CI 7.8%-17.8%);非荷包缝合(6项研究,306例)TWL为6.5%(95%CI 4.5%-8.4%),未达到PIVI阈值。
  • 汇总严重不良事件率为1.5%(95%CI 0.8%-2.6%;P < .0001)。

关键数值与推荐

  • PIVI预设有效性阈值为12个月TWL ≥5%,TORe达到该阈值。
  • PIVI预设安全性阈值为严重不良事件率 ≤5%,TORe达到该阈值。

临床怎么用

  • TORe可作为Roux-en-Y胃旁路术后体重反弹患者的内镜减重选择,符合ASGE PIVI标准。
  • 缝合式TORe中,荷包缝合模式可能与更优减重相关,选择术式时可参考。

局限性

  • 折叠式TORe亚组仅纳入1项研究110例患者,证据有限。
  • 本PIVI评估将随新数据更新。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Roux-en-Y gastric bypass is a bariatric surgery associated with durable long-term weight loss in most, but not all, patients. Transoral outlet reduction (TORe) is an endoscopic procedure that reduces the gastrojejunostomy diameter and gastric pouch volume to promote weight loss in patients with recurrent weight gain after Roux-en-Y gastric bypass. This systematic review and meta-analysis, conducted by the Association for Bariatric Endoscopy in collaboration with the American Society for Gastrointestinal Endoscopy (ASGE) Technology Committee, aimed to evaluate whether TORe meets the performance thresholds outlined in the ASGE preservation and incorporation of valuable endoscopic innovations (PIVI) document for the clinical adoption of endoscopic bariatric therapies. At 12 months post-TORe, the pooled total weight loss (TWL) across 12 studies (1154 patients) was 8.9% (95% confidence interval [CI], 6.5%-11.3%; P < .0001), meeting the prespecified PIVI threshold of 5% TWL. Subgroup analysis by device showed comparable 12-month weight loss with either suturing TORe (11 studies, 1043 patients) or plication TORe (1 study, 110 patients), achieving 8.9% (95% CI, 6.2%-11.5%) TWL and 9.5% (95% CI, 7.8%-11.3%) TWL, respectively (P = .07). Subgroup analysis by suture pattern demonstrated significantly greater weight loss with the pursestring suture pattern (5 studies, 687 patients), achieving 12.8% TWL (95% CI, 7.8%-17.8%), whereas non-pursestring patterns (6 studies, 306 patients) yielded 6.5% TWL (95% CI, 4.5%-8.4%), which did not meet the PIVI threshold. The pooled serious adverse event rate across 15 studies (1373 patients) was 1.5% (95% CI, 0.8%-2.6%; P < .0001), meeting the PIVI threshold of ≤5% for serious adverse events. In summary, this PIVI assessment determined that the TORe procedure meets the ASGE PIVI thresholds for both effectiveness and safety, supporting its clinical adoption regardless of the device used. For suturing TORe, the pursestring suture pattern appears to be associated with superior outcomes compared to other suturing techniques. This PIVI assessment will be updated as additional data become available.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Jirapinyo P, Kumar N, Thompson CC, et al. Association for Bariatric Endoscopy systematic review and meta-analysis assessing the American Society for Gastrointestinal Endoscopy preservation and incorporation of valuable endoscopic innovations thresholds for transoral outlet reduction. Gastrointest Endosc. 2025. PMID: 40711436. doi:10.1016/j.gie.2025.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。